Susquehanna International Group’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-352,600
| Closed | -$60.7M | – | 14446 |
|
|
2021
Q3 | $60.7M | Buy |
352,600
+333,000
| +1,699% | +$43.6M | 0.01% | 1041 |
|
|
2021
Q2 | $2.46M | Sell |
19,600
-13,000
| -40% | -$1.64M | ﹤0.01% | 5453 |
|
|
2021
Q1 | $4.42M | Sell |
32,600
-95,600
| -75% | -$12.3M | ﹤0.01% | 4150 |
|
|
2020
Q4 | $16.4M | Buy |
128,200
+87,900
| +218% | +$10.3M | ﹤0.01% | 1955 |
|
|
2020
Q3 | $4.54M | Buy |
40,300
+7,800
| +24% | +$776K | ﹤0.01% | 3186 |
|
|
2020
Q2 | $3.1M | Sell |
32,500
-36,300
| -53% | -$3.5M | ﹤0.01% | 3748 |
|
|
2020
Q1 | $6.18M | Buy |
68,800
+51,800
| +305% | +$4.03M | ﹤0.01% | 2310 |
|
|
2019
Q4 | $901K | Sell |
17,000
-35,400
| -68% | -$1.61M | ﹤0.01% | 5737 |
|
|
2019
Q3 | $2.07M | Buy |
52,400
+35,600
| +212% | +$1.54M | ﹤0.01% | 4108 |
|
|
2019
Q2 | $690K | Buy |
16,800
+100
| +0.6% | +$4.14K | ﹤0.01% | 6547 |
|
|
2019
Q1 | $778K | Sell |
16,700
-38,300
| -70% | -$1.68M | ﹤0.01% | 5487 |
|
|
2018
Q4 | $2.4M | Sell |
55,000
-14,400
| -21% | -$719K | ﹤0.01% | 3262 |
|
|
2018
Q3 | $3.97M | Sell |
69,400
-158,300
| -70% | -$7.78M | ﹤0.01% | 2969 |
|
|
2018
Q2 | $11M | Buy |
227,700
+184,200
| +423% | +$6.71M | ﹤0.01% | 1832 |
|
|
2018
Q1 | $1.7M | Sell |
43,500
-11,600
| -21% | -$493K | ﹤0.01% | 4233 |
|
|
2017
Q4 | $2.34M | Buy |
+55,100
| New | +$2.07M | ﹤0.01% | 3631 |
|
|
2017
Q3 | – | Sell |
-38,700
| Closed | -$1.18M | – | 9932 |
|
|
2017
Q2 | $1.18M | Buy |
+38,700
| New | +$1.12M | ﹤0.01% | 4929 |
|
|
2017
Q1 | – | Sell |
-13,400
| Closed | -$342K | – | 10359 |
|
|
2016
Q4 | $342K | Sell |
13,400
-37,200
| -74% | -$1.18M | ﹤0.01% | 7732 |
|
|
2016
Q3 | $1.83M | Buy |
50,600
+31,200
| +161% | +$1.03M | ﹤0.01% | 3710 |
|
|
2016
Q2 | $659K | Buy |
+19,400
| New | +$631K | ﹤0.01% | 5642 |
|
|
2016
Q1 | – | Sell |
-16,800
| Closed | -$819K | – | 9910 |
|
|
2015
Q4 | $819K | Sell |
16,800
-40,400
| -71% | -$1.45M | ﹤0.01% | 5815 |
|
|
2015
Q3 | $1.42M | Buy |
57,200
+26,700
| +88% | +$802K | ﹤0.01% | 4985 |
|
|
2015
Q2 | $965K | Sell |
30,500
-8,400
| -22% | -$271K | ﹤0.01% | 6292 |
|
|
2015
Q1 | $1.48M | Sell |
38,900
-45,600
| -54% | -$1.81M | ﹤0.01% | 4947 |
|
|
2014
Q4 | $3.29M | Buy |
84,500
+49,500
| +141% | +$1.73M | ﹤0.01% | 3573 |
|
|
2014
Q3 | $1.06M | Sell |
35,000
-9,000
| -20% | -$254K | ﹤0.01% | 5807 |
|
|
2014
Q2 | $1.5M | Buy |
+44,000
| New | +$1.47M | ﹤0.01% | 5236 |
|
Susquehanna International Group's XLRN Position: Q4 2021 in Review
Susquehanna International Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 384,210 shares — an estimated $66.1M sold.
Susquehanna International Group first reported a position in XLRN in Q2 2014 and held it in 17 quarters. The position peaked at $66.1M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Susquehanna International Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Susquehanna International Group sold 384,210 Acceleron Pharma shares in Q4 2021, an estimated $66.1M.
- Susquehanna International Group first reported a position in Acceleron Pharma in Q2 2014 and held it in 17 quarters.
- Susquehanna International Group's Acceleron Pharma position peaked at $66.1M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.